The Value Signal — October 01, 2026

756 articles scanned · 15 high-signal

Signal Map

Executive Summary

Washington is tightening payment integrity on every front, from risk scores and audits to drug prices and 340B ledgers, while purchasers shift dollars toward demonstrable outcomes.

Risk adjustment enforcement remains the sharpest edge of federal oversight, with Independence Blue Cross agreeing to pay $22.5M to resolve False Claims Act allegations, according to Justice. Scrutiny now runs in both directions: Medical Economics reports that practice leaders want insurers to pay when downcoding audits come up empty, a push for audit symmetry that MA plans should expect to hear more of. On Medicare Advantage economics, AJMC reports that CMS projects a 16.5% drop in 2027 MA premiums, a figure that sits awkwardly beside the market's coverage retrenchment. Modern Healthcare finds MA insurers pulling back even further and refugees set to lose Medicaid coverage under the Trump tax law.

Pricing and performance are converging. Fierce Healthcare reports that CMS has finalized a model aimed at bringing most-favored nation pricing to Part B, while a PHTI survey it covers finds employers increasingly tying digital health payments to outcomes. Pharmaceutical Commerce frames the global backdrop through the EU's pharma package and specialty drug tariff exemptions, a reminder that manufacturer margin pressure is not confined to Medicare. 340B transparency is the next frontier: HFMA reports that the 2027 proposed Physician Fee Schedule would require hospitals to submit 340B-related Medicare Part D claims data to a centralized repository starting Jan. 1. Meanwhile, on the CMMI front, AAPC reports that Medicare is testing ACCESS to improve chronic care through technology, signalling that the Innovation Center still sees tech-enabled management as a lever for value.